Current Hypertension Reports

, Volume 5, Issue 3, pp 199–207 | Cite as

Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia

  • Stefan John
  • Roland E. Schmieder


This review focuses on the role of impaired endothelial function for the development of atherosclerosis in human arterial hypertension and hypercholesterolemia in vivo. Potential mechanisms underlying impaired endothelial function and decreased bioavailability of nitric oxide under these clinical conditions are discussed. It further addresses therapeutic strategies aimed at improving the bioavailability of nitric oxide in these patients. The overall conclusion is that the bioavailability of nitric oxide is probably impaired, not by a single defect, but by various mechanisms affecting nitric oxide synthesis as well as nitric oxide breakdown. In both diseases increased superoxide anion production and oxidative stress represent a major mechanism. Decreased bioavailability of nitric oxide not only impairs endothelium-dependent vasodilation, but also activates other mechanisms that play an important role in the pathogenesis of atherosclerosis. Thus, therapeutic strategies should aim to restore bioavailability of nitric oxide, which has been demonstrated for lipid-lowering therapy in hypercholesterolemia and blood pressure control in hypertension. In addition, antioxidative strategies will represent a major therapeutic tool against atherosclerotic diseases in the future. Statins and blockers of the renin-angiotensin system seem to have such antioxidative effects independent from their effects on lipid profiles or blood pressure control.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373–376.PubMedCrossRefGoogle Scholar
  2. 2.
    Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524–526.PubMedCrossRefGoogle Scholar
  3. 3.
    Palmer RMJ, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988, 333:664–666.PubMedCrossRefGoogle Scholar
  4. 4.
    Vallance P, Collier J, Moncada S: Effects of endotheliumderived nitric oxide on peripheral arteriolar tone in man. Lancet 1989, 2:997–1000.PubMedCrossRefGoogle Scholar
  5. 5.
    Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801–809.PubMedCrossRefGoogle Scholar
  6. 6.
    De Caterina R, Libby P, Peng HB, et al.: Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995, 96:60–68.PubMedGoogle Scholar
  7. 7.
    Radomski MW, Moncada S: Regulation of vascular homeostasis by nitric oxide. Thromb Haemost 1993, 70:36–41.PubMedGoogle Scholar
  8. 8.
    Draijer R, Atsma DE, Van der Laarse A, van Hinsbergh VW: CGMP and nitric oxide modulate thrombin-induced endothelial permeability: regulation via different pathways in human aortic and umbilical vein endothelial cells. Circ Res 1995, 76:199–208.PubMedGoogle Scholar
  9. 9.
    Garg UC, Hassid A: Nitric oxide generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989, 83:1774–1777.PubMedGoogle Scholar
  10. 10.
    Cayatte AJ, Palacino JJ, Horten K, Cohen RA: Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994, 14:753–759.PubMedGoogle Scholar
  11. 11.
    Benzuly KH, Padgett RC, Kaul S, et al.: Functional improvement precedes structural regression of atherosclerosis. Circulation 1994, 90:1585.Google Scholar
  12. 12.
    Anggard E: Nitric oxide: mediator, murderer and medicine. Lancet 1994, 343:1199–1206.PubMedCrossRefGoogle Scholar
  13. 13.
    Vanhoutte PM: How to assess endothelial function in human blood vessels. J Hypertens 1999, 17:1047–1058.PubMedCrossRefGoogle Scholar
  14. 14.
    Benjamin N, Calver A, Collier J, et al.: Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995, 25:918–923.PubMedGoogle Scholar
  15. 15.
    Anderson TJ, Uehata A, Gerhard MD, et al.: Close relation of endothelial function in the coronary and peripheral circulations. J Am Coll Cardiol 1995, 26:1235–1241.PubMedCrossRefGoogle Scholar
  16. 16.
    Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990, 323:22–27.PubMedGoogle Scholar
  17. 17.
    Linder L, Kiowsky W, Buhler FR, Luscher TF: Direct evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted responses in essential hypertension. Circulation 1990, 81:1762–1767.PubMedGoogle Scholar
  18. 18.
    Treasure CB, Klein JL, Vita JA, et al.: Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993, 87:86–93.PubMedGoogle Scholar
  19. 19.
    Creager MA, Cooke JP, Mendelsohn ME, et al.: Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990, 86:228–234.PubMedGoogle Scholar
  20. 20.
    Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM: Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992, 340:1430–1432.PubMedCrossRefGoogle Scholar
  21. 21.
    Suwaidi JA, Hamasaki S, Higano ST, et al.: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:1899–1906.Google Scholar
  22. 22.
    Halcox JPJ, Schenke WH, Zalos G, et al.: Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002, 106:653–658. This study documents that assessment of coronary endothelial dysfunction can predict acute cardiovascular events in patients with and without coronary artery disease, providing additional information that complements angiographic and risk factor assessment.PubMedCrossRefGoogle Scholar
  23. 23.
    Perticone F, Ceravolo R, Pujia A, et al.: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001, 104:191–196. An important study that demonstrates that forearm endothelial dysfunction is a marker of future cardiovascular events in patients with essential hypertension.PubMedGoogle Scholar
  24. 24.
    Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA: Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993, 87:1468–1474.PubMedGoogle Scholar
  25. 25.
    Leiper J, Vallance P: Biologic significance of endogenous methylargines that inhibit nitric oxide synthase. Cardiovasc Res 1999, 43:542–548.PubMedCrossRefGoogle Scholar
  26. 26.
    Böger RH, Bode-Böger SM, Szuba A, et al.: Asymetric Dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction - Its role in hypercholesterolemia. Circulation 1998, 98:1842–1847.PubMedGoogle Scholar
  27. 27.
    Lundman P, Eriksson MJ, Stühlinger M, et al.: Mild-to-moderate Hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001, 38:111–116.PubMedCrossRefGoogle Scholar
  28. 28.
    Päivä H, Laakso J, Laine H, et al.: Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol 2002, 40:1241–1247. This study demonstrates that subjects with borderline hypertension have significantly increased ADMA concentration and that this is related to endothelial function independent of blood pressure elevation and hypercholesterolemia.PubMedCrossRefGoogle Scholar
  29. 29.
    Miyazaki H, Matsuoka H, Cooke JP, et al.: Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis. Circulation 1999, 99:1141–1146.PubMedGoogle Scholar
  30. 30.
    Drexler H, Zeiher AM, Meinzer K, Just H: Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991, 338:1546–1550.PubMedCrossRefGoogle Scholar
  31. 31.
    Cooke JP: Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000, 20:2032–2037.PubMedGoogle Scholar
  32. 32.
    Jessup W: Oxidized lipoproteins and nitric oxide. Curr Opin Lipidol 1996, 7:274–280.PubMedGoogle Scholar
  33. 33.
    Rosenkranz-Weiss P, Sessa WC, Milstein S, et al.: Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells: elevations in tetrahydrobiopterin levels enhance endothelial nitric oxiden synthase specific activity. J Clin Invest 1994, 93:2236–2243.PubMedGoogle Scholar
  34. 34.
    Griendling KK, Alexander RW: Oxidative stress and cardiovascular disease. Circulation 1997, 96:3264–3265.PubMedGoogle Scholar
  35. 35.
    Beckman JS, Koppenol WH: Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol 1996, 271:C1424-C1437.PubMedGoogle Scholar
  36. 36.
    Gryglewski RJ, Palmer RM, Moncada S: Superoxide anion is involved in the breakdown of endothelium derived vascular relaxing factor. Nature 1986, 320:456–456.CrossRefGoogle Scholar
  37. 37.
    Ohara Y, Peterson TE, Harrison GD: Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993, 91:2546–2551.PubMedGoogle Scholar
  38. 38.
    Mügge A, Brandes RP, Böger RH, et al.: Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 1994, 24:994–998.PubMedCrossRefGoogle Scholar
  39. 39.
    Mügge A, Helwell JH, Peterson TE, et al.: Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxation in cholesterol-fed rabbits. Circ Res 1991, 69:1293–1300.PubMedGoogle Scholar
  40. 40.
    Nakazono K, Watanabe N, Matsuno K, et al.: Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991, 88:10045–10048.PubMedCrossRefGoogle Scholar
  41. 41.
    Solzbach U, Hornig B, Jeserich M, Just H: Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 1997, 96:1513–1519.PubMedGoogle Scholar
  42. 42.
    Taddei S, Virdis A, Ghiadoni L, et al.: Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998, 97:2222–2229.PubMedGoogle Scholar
  43. 43.
    Ting HH, Timimi FK, Haley EA, et al.: Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 1997, 95:2617–2622.PubMedGoogle Scholar
  44. 44.
    Pritchard KA, Groszek L, Smalley DM, et al.: Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995, 77:510–518.PubMedGoogle Scholar
  45. 45.
    Kwon NS, Nathan CF, Stuher DJ: Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J Biol Chem 1989, 264:20496–20501.PubMedGoogle Scholar
  46. 46.
    Cosentino F, Katusic Z: Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995, 91:139–144.PubMedGoogle Scholar
  47. 47.
    Stroes ESG, Kastelein JJ, Cosentino F, et al.: Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997, 99:41–46.PubMedCrossRefGoogle Scholar
  48. 48.
    Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured smooth muscle cells. Circ Res 1994, 74:1141–1148.PubMedGoogle Scholar
  49. 49.
    Nickenig G, Sachinidis A, Michaelsen F, et al.: Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997, 95:473–478.PubMedGoogle Scholar
  50. 50.
    Warnholtz A, Nickenig G, Schulz E, et al.: Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999, 99:2027–2033.PubMedGoogle Scholar
  51. 51.
    John S, Delles C, Klingbeil AU, et al.: LDL-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans. J Hypertens 1999, 17:1933–1939.PubMedCrossRefGoogle Scholar
  52. 52.
    Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.CrossRefGoogle Scholar
  53. 53.
    Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1350–1351.CrossRefGoogle Scholar
  54. 54.
    Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996, 335:1001–1009.PubMedCrossRefGoogle Scholar
  55. 55.
    Bellosta S, Bernini F, Ferri N, et al.: Direct vascular effects of HMGCoA reductase inhibitors. Atherosclerosis 1998, 137:S101-S109.PubMedCrossRefGoogle Scholar
  56. 56.
    Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW: Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol lowering actions. J Am Coll Cardiol 1999, 33:234–241.PubMedCrossRefGoogle Scholar
  57. 57.
    Wagner AH, Koehler T, Rueckschloss U, et al.: Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000, 20:61–69.PubMedGoogle Scholar
  58. 58.
    John S, Schlaich M, Langenfeld M, et al.: Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients - a randomized, placebo-controlled, double-blind study. Circulation 1998, 98:211–216.PubMedGoogle Scholar
  59. 59.
    Anderson TJ, Meredith IT, Yeung AC, et al.: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995, 332:488–493.PubMedCrossRefGoogle Scholar
  60. 60.
    John S, Delles C, Jacobi J, Schlaich MP, et al.: Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001, 37:1351–1358. This study demonstrates that statins can rapidly improve the bioavailability of nitric oxide, probably independent of their lipid-lowering action.PubMedCrossRefGoogle Scholar
  61. 61.
    Rikitake Y, Kawashima S, Takeshita S, et al.: Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol fed rabbits. Atherosclerosis 2001, 154:87–96.PubMedCrossRefGoogle Scholar
  62. 62.
    Nickenig G, Bäumer AT, Temur Y, et al.: Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999, 100:2131–2134.PubMedGoogle Scholar
  63. 63.
    Wassmann S, Laufs U, Baumer AT, et al.: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001, 37:1450–1457. This important animal study shows that statins can improve endothelial dysfunction in hypertension mediated by a reduction of free radical release in the vasculature, Thus, statins may be used not only as lipid-lowering drugs but also as antiatherosclerotic substances in patients with hypertension.PubMedGoogle Scholar
  64. 64.
    Kalinowski L, Dobrucki LW, Brovkovych V, Malinski T: Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic efect of cerivastatin. Circulation 2002, 105:933–938. Direct measurement of biologically active NO and O2 - in endothelium in vitro shows that statins increase NO activity by acivation of NO release and by concurrent inactivation of O2 -.PubMedCrossRefGoogle Scholar
  65. 65.
    John S, Schneider M, Delles C, et al.: Lipid independent effects of statins on endothelial function. J Hypertens 2002, 20 (suppl 4):44.Google Scholar
  66. 66.
    Lyons D, Webster J, Benjamin N: The effect of antihypertensive therapy on responsiveness to local intra-arterial NG-monomethyl-L-arginine in patients with essential hypertension. J Hypertens 1994, 12:1047–1052.PubMedGoogle Scholar
  67. 67.
    Panza JA, Quyyumi AA, Callahan TS, Epstein SE: Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J Am Coll Cardiol 1993, 21:1145–1151.PubMedGoogle Scholar
  68. 68.
    Schiffrin EL, Deng LY: Comparison of effects of angiotensin Iconverting enzyme inhibition and β-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 1995, 25:699–703.PubMedGoogle Scholar
  69. 69.
    Schiffrin EL, Park JB, Intengan HD, Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000, 101:1653–1659.PubMedGoogle Scholar
  70. 70.
    Mühlen B, Kahan T, Hägg A, et al.: Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens 2001, 19:1813–1818.CrossRefGoogle Scholar
  71. 71.
    Ghiadoni L, Virdis A, Magagna A, et al.: Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000, 35:501–506.PubMedGoogle Scholar
  72. 72.
    Creager MA, Roddy MA: Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994, 24:499–505.PubMedGoogle Scholar
  73. 73.
    Wassmann S, Hilgers S, Laufs U, et al.: Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002, 22:1208–1212. This study proves that AT1 receptor blockers can improve endothelial dysfunction also in hypercholesterolemia, providing evidence that these substances are not only antihypertensive but also antiatherosclerotic drugs.PubMedCrossRefGoogle Scholar
  74. 74.
    Wiemer G, Scholkens BA, Busse R, et al.: The functional role of angiotensin II subtype AT2-receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett 1993, 3:24–27.Google Scholar
  75. 75.
    Klingbeil A, John S, Schneider MP, et al.: Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003, 16:123–128.PubMedCrossRefGoogle Scholar
  76. 76.
    Tzemos N, Lim PO, MacDonald TM: Nebivolol reverses endothelial dysfunction in essential hypertension. Circulation 2001, 104:511–514.PubMedGoogle Scholar
  77. 77.
    Dandona P, Karne R, Ghanim H, et al.: Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000, 101:122–124.PubMedGoogle Scholar
  78. 78.
    Frielingsdorf J, Seiler C, Kauffman P, et al.: Normalization of anbormal coronary vasomotion by calcium antagonists in patients with hypertension. Circulation 1996, 93:1380–1387.PubMedGoogle Scholar
  79. 79.
    Taddei S, Virdis A, Ghiadoni L, et al.: Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress essential hypertensive patients. J Hypertens 2001, 19:1379–1386.PubMedCrossRefGoogle Scholar
  80. 80.
    Taddei S, Virdis A, Ghiadoni L, et al.: Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension 2001, 37:943–948.PubMedGoogle Scholar
  81. 81.
    Mak TI, Boehme P, Weglicki WB: Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Circ Res 1992, 70:1099–1103.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Stefan John
  • Roland E. Schmieder
    • 1
  1. 1.Department of Medicine IVUniversity of Erlangen-Nürnberg, Klinikum Nürnberg-SüdNürnbergGermany

Personalised recommendations